Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection

NCT04366830 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19

Interventions

DRUG: Remestemcel-L

Sponsor

Mesoblast International Sàrl